Still possible to control monkeypox outbreak, says former FDA chief

Former US Food and Drugs Administration (FDA) chief Scott Gottlieb said that the response to the virus has to be wider to control it, though.

Monkeypox
Monkeypox (Illustration: Reuters)
IANS New York
2 min read Last Updated : Aug 09 2022 | 7:42 PM IST

Despite the US declaring monkeypox a public health emergency, former US Food and Drugs Administration (FDA) chief Scott Gottlieb said that it is possible to prevent it from becoming an endemic virus -- a prospect officials likely failed with Covid-19.

Gottlieb said that the response to the virus has to be wider to control it, though.

Currently, testing has mainly been reserved for just gay and bisexual men -- who make up an overwhelming majority of cases, he said, the DailyMail reported, citing CBS. Gottlieb believes that more cases would be found if testing was expanded beyond just that community.

His comments come days after the US Department of Health and Human Services (HHS) declared a public health emergency over the virus last week.

Last week, Gottlieb said should the disease become endemic, it would be a serious failure because this could have been prevented.

He noted that -- unlike when Covid first emerged -- there were already reliable vaccines and tests available to stop the disease in its tracks. But the Centers for Disease Control and Prevention (CDC) failed to act rapidly, instead following the same 'protracted checklist' and making many of the same mistakes as when Covid struck.

He, recently, wrote in the New York Times that should the disease gain a foothold, it would be a disaster both because it could have been prevented and because infections -- which spark blisters across the body -- are painful. Many sufferers have said their symptoms were "worse than Covid".

--IANS

vc/vd

 

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :MonkeypoxUS FDAUnited Stateshealth care

First Published: Aug 09 2022 | 7:42 PM IST

Next Story